PLYX Polaryx Therapeutics
Polaryx Therapeutics earnings company data as of 4:48 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -0.03 | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by PLYX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $368K bought by 2 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Alex Keun Mo Yang CEO, +1 joint filerBuy$360K 88,453 shares at $4.07 +0.4% to stakeTraded May 27 Filed May 28
-
G. Michael Landis CFOBuy$7,991 2,867 shares at $2.79 +1.3% to stakeTraded Feb 18 Filed Feb 20
SEC filings
Recent issuer filings from EDGAR, 15 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.07 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| DEF 14A | PROXY STATEMENT | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.08,8.01 | Filing Doc | |
| 8-K | 1.01,3.02,7.01,9.01 | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| 10-K | ANNUAL REPORT | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 424B4 | PROSPECTUS | Filing Doc | |
| S-1/A | REGISTRATION STATEMENT | Filing Doc | |
| S-1/A | REGISTRATION STATEMENT | Filing Doc | |
| S-1 | REGISTRATION STATEMENT | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.